Background: Cardiac troponin T is often elevated in hemodialysis patients, even without apparent heart disease. Cardiac troponin T has been used to predict mortality and morbidity among asymptomatic dialysis patients. However, only a single retrospective study has reported that higher IV iron use was associated with higher troponin levels; therefore, it remains unclear whether IV iron therapy could influence troponin levels and thus affect patients’ outcomes.

Methods: A cross-sectional study was conducted from February 2023 to October 2024 at the dialysis unit. We included 244 patients who had been on hemodialysis for more than 3 months, were on IV iron therapy, and were aged 18 years or older. High-sensitivity troponin T level (h-cTnT) was measured before the start of the dialysis session, and patients were stratified into two groups based on h-cTnT (≤ 60 ng/L and > 60 ng/L).

Results: Among 224 hemodialysis patients (137 male, 87 female; mean age of 59.96 ± 13.02 years). The average IV iron dose was 255.5 ± 143.0 mg/month. hs-TnT levels averaged 90.5 ± 89.4 ng/L, with 58.5% (131 patients) have h-cTnT level > 60 ng/L. No significant relationship between IV iron and h-cTnT was found. However, higher h-cTnT levels were significantly associated with male gender, age, ischemic heart disease, cerebrovascular accidents, statin use, and doxazosin. The > 60 ng/L group had a significantly lower processed blood volume (p = 0.038), shorter effective treatment time (p = 0.021), and lower KT/V urea (p = 0.008). Albumin levels were also lower in this group (p = 0.018).

Conclusion: There is no statistically significant relationship between h-cTnT and IV iron. However, these results don’t eliminate the importance of IV iron therapy in hemodialysis patients.

Title

BMC Nephrology

Publisher

BioMed Central Ltd

Publisher Country

United Kingdom

Indexing

Scopus

Impact Factor

2.4

Publication Type

Both (Printed and Online)

Volume

26

Year

2025

Pages

--